Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 1997

View Archived Issues

Use of desbutylhalofantrine for malaria claimed

ICE and apoptosis inhibitors disclosed by SmithKline Beecham

Antineoplastic cryptophycin compounds

Novel dopamine receptor ligands from Purdue Research Foundation/UNC

Lilly reports compounds for postmenopausal syndrome

Merck & Co. prepares cytokine inhibitors

Ibogamine congeners for addiction

Fluoxetine for the management of premature ejaculation

In vitro antitumor activity of lactoferrin

Mechanism of impaired erection with finasteride elucidated

Transurethral alprostadil/prazosin for erectile dysfunction

Nasacort now available for the treatment of allergic rhinitis

Moxisylyte recommended as first-line therapy for erectile dysfunction

Melanotropic peptide effective in men with erectile dysfunction

Initial clinical results with vinpocetine for urge incontinence

Nitrosylated alpha-adrenoceptor antagonists for erectile dysfunction

New COX-2 inhibitor from Searle

Nasal midazolam safe and effective for anterograde amnesia in children undergoing VCUG

DuPont Merck reports orally active acetylcholine release enhancer

Furosemide vs. placebo for nocturnal polyuria

TGF-beta1 antisense vaccine effective in rat prostate cancer model

GG-745 compared to finasteride in BPH patients

Natural interferon gamma introduced in Japan

Schering-Plough's Nasonex approved in U.K. and France

Norian seeks FDA approval for orthopedic applications of Norian SRS

Faulding launches wound care line in Australia and New Zealand

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...